-   Training & Support

[Expand/Collapse all sections]Expand all

For information on how to process a PBS Authority see Processing Complex
Authority Required Listings. Contact a Local Peer Support (LPS) if
unsure of how to action an application.

On this page:

Blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib applications

Blinatumomab quick reference

Dasatinib quick reference

Imatinib quick reference

Inotuzumab ozogamicin quick reference

Ponatinib quick reference

Blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib applications

Table 1

+-----------------------------------+-----------------------------------+
| Step                              | Action                            |
+-----------------------------------+-----------------------------------+
| 1                                 | Dasatinib and imatinib and ‘first |
|                                   | line’ applications                |
|                                   |                                   |
|                                   | There is a lifetime maximum of 24 |
|                                   | months of continuing treatment.   |
|                                   |                                   |
|                                   | The patient may switch between    |
|                                   | ‘first line’ dasatinib or         |
|                                   | imatinib treatment due to         |
|                                   | toxicity or intolerance.          |
+-----------------------------------+-----------------------------------+
| 2                                 | Blinatumomab only applications    |
|                                   |                                   |
|                                   | Induction treatment is limited to |
|                                   | a maximum of 2 treatment cycles   |
|                                   | in a patient’s lifetime           |
|                                   |                                   |
|                                   | Consolidation treatment is        |
|                                   | limited to                        |
|                                   |                                   |
|                                   | -   a maximum of 3 treatment      |
|                                   |     cycles in a patient’s         |
|                                   |     lifetime for relapsed or      |
|                                   |     refractory, or                |
|                                   | -   two treatment cycles in a     |
|                                   |     patient's lifetime for        |
|                                   |     measurable residual disease   |
|                                   |                                   |
|                                   | The Online PBS Authorities system |
|                                   | will reject applications for      |
|                                   | treatment beyond the maximum      |
|                                   | allowed. If the prescriber needs  |
|                                   | a top up or replacement the       |
|                                   | assessment may need to be         |
|                                   | overridden                        |
+-----------------------------------+-----------------------------------+
| 3                                 | Inotuzumab applications           |
|                                   |                                   |
|                                   | -   Induction treatment is        |
|                                   |     limited to a maximum of 3     |
|                                   |     treatment cycles in a         |
|                                   |     patient’s lifetime            |
|                                   | -   Consolidation treatment is    |
|                                   |     limited to a maximum of 5     |
|                                   |     treatment cycles in a         |
|                                   |     patient’s lifetime            |
|                                   | -   Patients are limited to a     |
|                                   |     maximum of 6 total treatment  |
|                                   |     cycles in a lifetime across   |
|                                   |     the induction and             |
|                                   |     consolidation treatment       |
|                                   |     restrictions                  |
+-----------------------------------+-----------------------------------+

Blinatumomab quick reference

Table 2

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Written - | No        | OPA       | N/A       | No        |
| (I        | S100      |           |           |           |           |
| nduction) |           |           |           |           |           |
|           |           |           |           |           |           |
| PB210     |           |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Tele      | No        | OPA       | N/A       | Yes       |
| ontinuing | phone/Ele |           |           |           |           |
| (Conso    | ctronic - |           |           |           |           |
| lidation) | S100      |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| In        | Te        | No        | OPA       | N/A       | Yes       |
| duction - | lephone/E |           |           |           |           |
| Balance   | lectronic |           |           |           |           |
| of Supply | – S100    |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Dasatinib quick reference

Table 3

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial – | Written - | Yes       | OPA       | N/A       | No        |
| first     | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| PB271     |           |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial – | Written – | Yes       | OPA       | N/A       | No        |
| second    | S85       |           |           |           |           |
| line      |           |           |           |           |           |
|           |           |           |           |           |           |
| PB077     |           |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Tele      | No        | OPA       | N/A       | Yes       |
| ontinuing | phone/Ele |           |           |           |           |
|           | ctronic - |           |           |           |           |
|           | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Change –  | Written – | Yes       | OPA       | N/A       | No        |
| whilst in | S85       |           |           |           |           |
| first     |           |           |           |           |           |
| line      |           |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
| (due to   |           |           |           |           |           |
| toxicity) |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Change –  | Te        | No        | OPA       | N/A       | Yes       |
| whilst in | lephone/E |           |           |           |           |
| first     | lectronic |           |           |           |           |
| line      | – S85     |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
| (due to   |           |           |           |           |           |
| toxicity) |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Imatinib quick reference

Table 4

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Te        | No        | OPA       | N/A       | No        |
|           | lephone - |           |           |           |           |
|           | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Stre      | No        | N/A       | N/A       | Yes       |
| ontinuing | amlined - |           |           |           |           |
|           | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Change –  | Telephone | No        | OPA       | N/A       | Yes       |
| whilst in | /E        |           |           |           |           |
| first     | lectronic |           |           |           |           |
| line      | – S85     |           |           |           |           |
| initial   |           |           |           |           |           |
| phase     |           |           |           |           |           |
| (due to   |           |           |           |           |           |
| toxicity) |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Change –  | St        | No        | N/A       | N/A       | Yes       |
| whilst in | reamlined |           |           |           |           |
| first     | – S85     |           |           |           |           |
| line      |           |           |           |           |           |
| c         |           |           |           |           |           |
| ontinuing |           |           |           |           |           |
| phase     |           |           |           |           |           |
| (due to   |           |           |           |           |           |
| toxicity) |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Inotuzumab ozogamicin quick reference

Table 5

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Written - | Yes       | OPA       | N/A       | No        |
| (I        | S100 EFC  |           |           |           |           |
| nduction) |           |           |           |           |           |
|           |           |           |           |           |           |
| PB269     |           |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Tele      | No        | OPA       | N/A       | Yes       |
| ontinuing | phone/Ele |           |           |           |           |
| (Conso    | ctronic - |           |           |           |           |
| lidation) | S100 EFC  |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

Ponatinib quick reference

Table 6:

+-----------+-----------+-----------+-----------+-----------+-----------+
| Res       | Authority | PA        | P         | P         | P         |
| trictions | level and | a         | rocessing | rescriber | rescriber |
|           | section   | ssessment | system    | type      | s         |
|           |           |           |           |           | elf-serve |
+-----------+-----------+-----------+-----------+-----------+-----------+
| Initial   | Written - | Yes       | OPA       | N/A       | No        |
|           | S85       |           |           |           |           |
| PB169     |           |           |           |           |           |
| form      |           |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+
| C         | Tele      | No        | OPA       | N/A       | Yes       |
| ontinuing | phone/Ele |           |           |           |           |
|           | ctronic - |           |           |           |           |
|           | S85       |           |           |           |           |
+-----------+-----------+-----------+-----------+-----------+-----------+

                                   

-   Services Australia ABN 90 794 605 008 
